In 2015, oncolytic virotherapy was approved for clinical use, and in 2017, recombinant
adeno-associated virus (AAV) delivery was also approved. However, systemic …

Immune checkpoint inhibitors (ICIs) have profoundly reshaped the treatment paradigm for
non-small cell lung cancer (NSCLC). Despite these advancements, primary and secondary …

Tumor necrosis factor (TNF) has been recognized as an immune activation factor in tumor
immunotherapy. Our study demonstrated that TNF blockade markedly enhanced the …

Non-small cell lung cancer (NSCLC) remains an unsolved challenge in oncology, signifying
a substantial global health burden. While considerable progress has been made in recent …

Immune checkpoint inhibitors have demonstrated modest efficacy as a monotherapy in
ovarian cancer. Originally developed to improve efficacy of T-cell therapies such as immune …

Interest surrounding the effect of irradiation on immune activation has exponentially grown
within the last decade. This includes work regarding mechanisms of the abscopal effect and …

Abstract Purpose: TILT-123 (igrelimogene litadenorepvec) is an oncolytic adenovirus armed
with tumor necrosis factor alpha and interleukin-2, designed to induce T-cell infiltration and …

Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality
worldwide. The discovery of specific driver mutations has revolutionized the treatment …

Background NOTCH1 is frequently mutated in non-small cell lung cancer (NSCLC), and also
is a poor therapeutic target. It is of clinical importance to investigate the effects of NOTCH1 …

Oncolytic adenoviral therapy is a promising approach for pancreatic cancer treatment.
However, the limited capacity of murine cells to produce infectious viral progeny precludes …